ST Germain D J Co. Inc. Grows Stock Position in Danaher Co. (NYSE:DHR)

ST Germain D J Co. Inc. boosted its stake in shares of Danaher Co. (NYSE:DHR) by 13.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 3,558 shares of the conglomerate’s stock after buying an additional 433 shares during the period. ST Germain D J Co. Inc.’s holdings in Danaher were worth $817,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Teachers Insurance & Annuity Association of America purchased a new stake in Danaher in the third quarter worth $39,000. MidAtlantic Capital Management Inc. purchased a new stake in Danaher in the third quarter worth $40,000. FSA Wealth Management LLC purchased a new stake in Danaher in the third quarter worth $50,000. Darwin Wealth Management LLC purchased a new stake in Danaher in the third quarter worth $55,000. Finally, Modus Advisors LLC purchased a new stake in Danaher in the fourth quarter worth $56,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of recent analyst reports. Evercore ISI increased their target price on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus increased their target price on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a research report on Thursday, October 31st. Finally, Raymond James dropped their price target on Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Price Performance

Shares of NYSE DHR opened at $235.08 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The company has a market cap of $169.79 billion, a PE ratio of 44.86, a P/E/G ratio of 4.33 and a beta of 0.83. The business has a 50-day simple moving average of $235.67 and a two-hundred day simple moving average of $253.73. Danaher Co. has a fifty-two week low of $222.53 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company’s quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter last year, the company earned $2.02 earnings per share. As a group, equities analysts expect that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.46%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.